Bluejay Diagnostics, Inc.
- Open
- 0.91
- Day high
- 0.91
- Day low
- 0.85
- Prev close
- 0.90
- Volume
- 506K
- Mkt cap
- $4M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.4
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $48K over the last 3 months (1 open-market buy, 1 sale)
- 🏛Institutions reducing (13F)
Bluejay Diagnostics, Inc. (BJDX) is a Healthcare company listed on NASDAQ. The stock is down 84% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 1 sale (SEC Form 4).
Bluejay Diagnostics, Inc. (BJDX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
BJDX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 12, 2026 | $-3520.00 | $-1.12 | +100.0% | — | — |
| May 13, 2026 | — | $-1.95 | — | — | — |
| Mar 6, 2026 | — | $-3.18 | — | — | — |
| Nov 7, 2025 | — | $-4.04 | — | — | — |
| Aug 7, 2025 | — | $-1.41 | — | — | — |
| Mar 31, 2025 | $-144.00 | $-112.37 | +22.0% | $216086 | — |
| Nov 7, 2024 | $-144.00 | $-8.00 | +94.4% | — | — |
| Aug 14, 2024 | $-144.00 | $-256.00 | -77.8% | — | — |
| May 15, 2024 | $-1152.00 | $-396.00 | +65.6% | — | — |
| Nov 9, 2023 | $-328.00 | $-832.00 | -153.7% | — | — |
| Aug 14, 2023 | $-600.00 | $-1100.00 | -83.3% | — | — |
| Mar 20, 2023 | $320.00 | $-960.00 | -400.0% | — | — |
BJDX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Wurth Douglas Clarkdirector | Grant | 100,000 | $2.08 |
| Aug 18, 2026 | Dey Svetlanadirector | Grant | 100,000 | $2.08 |
| Aug 18, 2026 | Dey Indranildirector, officer: President and CEO | Grant | 28,000 | — |
| Aug 18, 2026 | CHASE DONALD Rdirector | Grant | 100,000 | $2.08 |
| Aug 18, 2026 | ZEIDMAN FRED Sdirector | Grant | 100,000 | $2.08 |
| Jul 13, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 34,938 | $1.40 |
| Jul 13, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 64,047 | $1.51 |
| May 18, 2026 | CHASE DONALD Rdirector | Buy | 12,500 | $2.00 |
| May 18, 2026 | Wurth Douglas Clarkdirector | Buy | 12,500 | $2.00 |
| May 18, 2026 | Dey Svetlanadirector | Buy | 12,500 | $2.00 |
| May 18, 2026 | ZEIDMAN FRED Sdirector | Buy | 12,500 | $2.00 |
| May 18, 2026 | Dey Indranildirector, officer: President and CEO | Buy | 12,500 | $2.00 |
| Dec 14, 2023 | Dey Svetlanadirector | Buy | 500 | $3.07 |
| Dec 14, 2023 | Dey Indranildirector, 10 percent owner, officer: President and CEO | Buy | 500 | $3.27 |
| Mar 31, 2023 | Dey Indranildirector, officer: President and CEO | Buy | 2,000 | $0.44 |
Source: BJDX SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full BJDX insider & 13F page →Bluejay Diagnostics, Inc. company profile
Overview
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) is a medical device company founded in 2015 and headquartered in Acton, Massachusetts. The company went public in November 2021 and focuses on developing point-of-care diagnostic solutions for healthcare providers. Bluejay operates in the early-stage medical diagnostics sector, developing innovative testing platforms designed to improve patient care through rapid, accurate diagnostic capabilities at the point of care.
Business
Bluejay Diagnostics operates in the point-of-care (POC) diagnostics industry, which involves medical testing devices that can be used directly where patient care occurs, rather than in centralized laboratories. This market serves the critical need for rapid diagnostic results that can inform immediate treatment decisions, particularly important in emergency rooms, urgent care centers, and physician offices. The company's primary focus is developing the Symphony platform, a comprehensive diagnostic technology system comprising two main components. The Symphony Fluorescence Immuno-analyzer is a sophisticated device that uses non-contact centrifugal force to orchestrate blood processing, isolate biomarkers, and prepare immunoassays - essentially automating the complex process of analyzing blood samples for specific disease markers. The Symphony Cartridge Library contains the reagents and components necessary for various diagnostic tests, functioning as consumable test kits that work with the analyzer. Bluejay also markets the ALLEREYE diagnostic test, a point-of-care device specifically designed for diagnosing allergic conjunctivitis (eye allergies). This represents the company's first commercially available product, targeting a specific but common medical condition that affects millions of patients annually. The company is developing additional biomarkers for detecting other serious medical conditions, including high-sensitivity troponin T/I (hsTNT/I) for detecting myocardial injury (heart attacks) and NT-proBNP for diagnosing cardiac heart failure. These represent significant market opportunities as cardiovascular diseases are leading causes of mortality worldwide and require rapid, accurate diagnosis for effective treatment.
Revenue model
Bluejay Diagnostics operates on a medical device sales and licensing model. The company generates revenue through direct sales of its diagnostic devices and consumable test cartridges to healthcare providers. The business model follows the classic "razor and blade" approach common in medical diagnostics, where the initial analyzer represents a capital equipment sale, while the ongoing cartridge sales provide recurring revenue streams as healthcare providers conduct tests. The company's paying customers are primarily healthcare institutions including hospitals, urgent care centers, physician offices, and other clinical settings that require rapid diagnostic capabilities. These customers value point-of-care testing because it enables immediate treatment decisions, reduces patient wait times, and can improve clinical outcomes compared to sending samples to external laboratories. Bluejay has established a licensing and supply agreement with Toray Industries, Inc., a major Japanese conglomerate, for manufacturing and distributing protein detection chips used in their diagnostic systems. This partnership provides access to advanced manufacturing capabilities and potentially broader distribution networks. Several factors could impact the company's margins and profitability. Positive factors include the growing demand for point-of-care testing driven by an aging population, increased focus on rapid diagnosis, and the trend toward decentralized healthcare delivery. The recurring revenue nature of consumable cartridge sales provides potential for improving margins over time as the installed base grows. Negative factors include intense competition from established diagnostic companies like Abbott, Roche, and Siemens, regulatory approval risks that can delay product launches, and the high costs associated with clinical trials and FDA approval processes. Additionally, healthcare reimbursement policies and hospital budget constraints can significantly impact adoption rates and pricing power.
Competitive moat
Bluejay Diagnostics currently operates with a relatively weak competitive moat in the highly competitive point-of-care diagnostics market. The company's primary potential advantages lie in its proprietary Symphony platform technology, which uses non-contact centrifugal force for blood processing - a potentially differentiated approach compared to traditional diagnostic methods. However, this technological differentiation has not yet been proven at commercial scale or demonstrated clear superiority over existing solutions. The company's partnership with Toray Industries provides some manufacturing and potentially distribution advantages, but this relationship alone does not constitute a strong moat. The point-of-care diagnostics market is dominated by large, well-established players with significant resources, extensive product portfolios, established customer relationships, and proven regulatory track records. Significant competitive threats come from industry giants like Abbott Laboratories (with their i-STAT system), Roche Diagnostics, Siemens Healthineers, and other established medical device companies that have the resources to develop competing technologies, navigate regulatory processes more efficiently, and leverage existing customer relationships. These competitors also have the advantage of cross-selling opportunities within their broader product ecosystems. The company's small size and limited commercial track record represent additional vulnerabilities. Bluejay lacks the scale economies, brand recognition, and customer loyalty that typically provide defensive moats in the medical device industry. The regulatory approval process for medical devices creates some barriers to entry, but these same regulations also pose significant risks for a small company with limited resources to navigate complex FDA approval processes.
Risks & safety
Bluejay Diagnostics presents significant financial risks with limited margin of safety for investors. Cash burn and solvency concerns: - Current quarterly cash burn rate of approximately $1.8 million based on Q1 2025 operating cash flow - Cash and short-term investments of $3.1 million as of Q1 2025, providing roughly 4-5 quarters of runway at current burn rate - Minimal revenue generation ($216K in Q4 2024, $0 in most recent quarters) creates ongoing funding pressure - Strong current ratio of 2.7 indicates short-term liquidity, but rapid cash depletion remains a concern Valuation metrics: - Market capitalization of approximately $3.4 million represents extremely low valuation - Price-to-book ratio of 0.53 suggests trading below book value - Graham Net-Net ratio of 3.08 indicates potential asset value, but this is offset by ongoing losses - Negative enterprise value due to cash exceeding market cap Other considerations: - No meaningful revenue base to support current operations - High R&D costs typical for early-stage medical device companies - Regulatory approval risks could delay revenue generation and require additional capital - Potential dilution risk from future equity fundraising to maintain operations
Recent development
Based on the available financial data, Bluejay Diagnostics has been in a development and commercialization phase over the past few years. The company achieved a notable milestone with some revenue generation in Q4 2024 ($216,086), representing its first meaningful revenue in recent quarters after multiple periods with zero revenue. This suggests potential progress in commercializing its ALLEREYE diagnostic test or other products. The company has maintained its strategic partnership with Toray Industries for protein detection chip manufacturing and distribution, which remains a key component of its go-to-market strategy. This relationship provides access to advanced manufacturing capabilities that would be prohibitively expensive for a small company to develop independently. Product development efforts have continued to focus on the Symphony platform development, with ongoing work on biomarkers for cardiovascular conditions including hsTNT/I for myocardial injury detection and NT-proBNP for heart failure diagnosis. These represent significant market opportunities given the prevalence of cardiovascular diseases and the clinical need for rapid cardiac biomarker testing. The company's financial position has deteriorated over the review period, with cash reserves declining from over $8 million in mid-2024 to approximately $3.1 million by Q1 2025, reflecting the ongoing cash burn associated with product development and commercialization efforts. This trend indicates increasing urgency for either revenue growth or additional capital raising to sustain operations.
BJDX company profile · for informational purposes only — not investment advice.
Track BJDX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free